Skip to content

Study · Randomized controlled trial · 1994

2 results

Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.

Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, De Matteis A, Zola P, Sismondi P, Francini G, Petrioli R

Annals of oncology : official journal of the European Society for Medical Oncology1 Apr 1994Cited by 86 (Europe PMC)

PMID8075030 (opens in a new tab)DOI10.1093/oxfordjournals.annonc.a058837 (opens in a new tab)PepBankPUB-08075030
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In perimenopausal metastatic breast cancer patients, survival was comparable irrespective of allocated treatment, including goserelin and surgical castration or ovarian irradiation, each with or without tamoxifen.

    In plain wordsIn patients with metastatic breast cancer, survival was comparable across all allocated treatments, including goserelin and surgical castration or ovarian irradiation.

    Peptide
    Goserelin
    Outcome
    Direction not reportedSurvival versus ovarian ablation
    Study

    n: not reported in source

    Comparator
    Other allocated arms: surgical castration or ovarian irradiation, and each with tamoxifen
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nevertheless, patient survivals were comparable, irrespective of allocated treatment.
    2 context sentences
    Summary · context
    Eighty-five perimenopausal patients with estrogen receptor or unknown positive metastatic breast cancer were randomly allocated to receive one of the following treatments: surgical castration (or ovarian irradiation); goserelin; surgical castration (or ovarian irradiation) plus tamoxifen; goserelin plus tamoxifen.
    Summary · context
    The study was performed according to a 2 x 2 factorial randomised design.
  2. 02HumanNon-randomized trialEfficacy outcome

    In perimenopausal metastatic breast cancer patients, response to goserelin alone was 27.2% (+/- 18.6).

    In plain wordsIn patients with metastatic breast cancer, response to goserelin alone was 27.2%.

    Peptide
    Goserelin
    Outcome
    Not applicableObjective response
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Response rate
    27.2%
    goserelin alone, reported +/- 18.6

    Source sentences

    Summary
    Response to goserelin and goserelin plus tamoxifen was 27.2% (+/- 18.6) and 45% (+/- 21.8), respectively.
    2 context sentences
    Summary · context
    Eighty-five perimenopausal patients with estrogen receptor or unknown positive metastatic breast cancer were randomly allocated to receive one of the following treatments: surgical castration (or ovarian irradiation); goserelin; surgical castration (or ovarian irradiation) plus tamoxifen; goserelin plus tamoxifen.
    Summary · context
    The study was performed according to a 2 x 2 factorial randomised design.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.